SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
 & Lead Plaintiff Deadline: April 14, 2017 - EconoTimes)
NEW YORK, March 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE:USNA) and certain of its officers, and is on behalf of purchasers of USANA securities between March 14, 2014 and February 7, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/usna.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) USANA’s BabyCare subsidiary had engaged in improper reimbursement practices in China; (2) these practices constituted violations of the Foreign Corrupt Practices Act; (3) consequently, USANA’s China revenues were in part the product of unlawful conduct and unlikely to be maintainable; (4) once the above mentioned conduct became public, USANA was likely subject to significant regulatory scrutiny; and (5) as a result, USANA’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/usna or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in USANA you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
